Terms: = Uterine cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Clinical Outcome
3 results:
1. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract] [Full Text] [Related]
2. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.
Manavi M; Hudelist G; Fink-Retter A; Gschwandtler-Kaulich D; Pischinger K; Czerwenka K
Gynecol Oncol; 2007 May; 105(2):418-26. PubMed ID: 17306351
[TBL] [Abstract] [Full Text] [Related]
3. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study.
Hudelist G; Czerwenka K; Singer C; Pischinger K; Kubista E; Manavi M
Cancer Genet Cytogenet; 2005 Apr; 158(1):35-42. PubMed ID: 15771902
[TBL] [Abstract] [Full Text] [Related]
